The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index; none of the 18 sources its claims cite is checked for support yet.
Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations
Open accessPublished version of a preprint
Abstract
A key public health need is to identify individuals at high risk for a given disease to enable enhanced screening or preventive therapies. Because most common diseases have a genetic component, one important approach is to stratify individuals based on inherited DNA variation1. Proposed clinical applications have largely focused on finding carriers of rare monogenic mutations at several-fold increased risk. Although most disease risk is polygenic in nature2–5, it has not yet been possible to use polygenic predictors to identify individuals at risk comparable to monogenic mutations. Here, we develop and validate genome-wide polygenic scores for five common diseases. The approach identifies 8.0, 6.1, 3.5, 3.2, and 1.5% of the population at greater than threefold increased risk for coronary artery disease, atrial fibrillation, type 2 diabetes, inflammatory bowel disease, and breast cancer, respectively. For coronary artery disease, this prevalence is 20-fold higher than the carrier frequency of rare monogenic mutations conferring comparable risk6. We propose that it is time to contemplate the inclusion of polygenic risk prediction in clinical care, and discuss relevant issues. Genome-wide polygenic risk scores derived from GWAS data for five common diseases can identify subgroups of the population with risk approaching or exceeding that of a monogenic mutation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
25 Own result · 10 Not checked yet · 7 Own method · 3 Own interpretation · 2 No basis given
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Moreover, even for our middle-aged study population, practicing clinicians could not identify the 8% of individuals at ≥3-fold risk based on GPSCAD in the absence of genotype information (Supplementary Table 8).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The polygenic predictor identified 3.5% of the population at ≥3-fold risk and the top 1% had 3.30-fold risk. (Tables 2 & 3).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Moreover, 0.1% of women had ≥5-fold risk of breast cancer—corresponding to a breast cancer prevalence of 19.0% in this group versus 4.2% in the remaining 99.9% of the distribution.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The polygenic predictor identified 6.1% of the population at ≥3-fold risk and the top 1% had 4.63-fold risk (Tables 2 & 3).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Moreover, 0.1% of women had ≥5-fold risk of breast cancer—corresponding to a breast cancer prevalence of 19.0% in this group versus 4.2% in the remaining 99.9% of the distribution.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The polygenic predictor identified 3.2% of the population at ≥3-fold risk and the top 1% had 3.87-fold risk (Tables 2 & 3).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This predictor performed equivalently well in the testing dataset, with AUC of 0.81.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plainn = 288,978- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Our results for CAD generalized to four other diseases: risk increased sharply in the right tail of the GPS distribution (Figure 3).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In our testing dataset, 19.8% of participants were at ≥3-fold increased risk for at least one of the five diseases studied (Table 2).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“GPSCAD performed substantially better than two previously published polygenic scores for coronary artery disease that included 50 and 49,310 variants, respectively (Supplementary Table 7 and Supplementary Fig. 1).17,18”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
What the sources say
- Not checked yetcites [17] Tada, H. et al. Risk prediction by genetic risk scores for coronary heart disease is independent of self-reported family history. Eur. Heart J. 37, 561–567 (2016). source
- Not checked yetcites [18] Abraham, G. et al. Genomic prediction of coronary heart disease. Eur. Heart J. 37, 3267–3278 (2016). source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 8
- Probably not a substantial claim. 6
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The predictors had AUC ranging from 0.79 – 0.81 in the validation set, with the best predictor (GPSCAD) involving 6,630,150 variants (Supplementary Table 1).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelationaln = 120,280- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Across the population, GPSCAD is normally distributed with the empirical risk of CAD rising sharply in the right tail of the distribution, from 0.8% in the lowest percentile to 11.1% in the highest percentile (Figure 2).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“In order to analyze individuals with a relatively homogenous ancestry and owing to small percentages of non-British individuals, the present analysis was restricted to the white British ancestry individuals.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Online Methods: > Testing cohort
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Whereas identifying carriers of rare monogenic mutations requires sequencing of specific genes and careful interpretation of the functional effects of mutations found, polygenic scores can be readily calculated for many diseases simultaneously, based on data from a single genotyping array.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The testing dataset was comprised of 288,978 UK Biobank Phase 2 participants distinct from those in the validation dataset described above.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Online Methods: > Testing cohort
plainn = 2- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Our validation and testing was performed in the UK Biobank population.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“These initial efforts were hampered by three challenges: (i) the small size of initial genome-wide association studies (GWAS), which affected the precision of the estimated impact of individual variants on disease risk; (ii) limited computational methods for creating GPS; and (iii) lack of large datasets needed to validate and test GPS.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The results above show that, for a number of common diseases, polygenic risk scores can now identify a substantially larger fraction of the population than found by rare monogenic mutations, at comparable or greater disease risk.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The vast majority of common disease occurs in individuals without rare monogenic mutations.
In the paper
“Individuals who volunteered for the UK Biobank tended to be more healthy than the general population;27”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
What the sources say
- Not checked yetcites [27] Fry, A. et al. Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population. Am. J. Epidemiol. 186, 1026–1034 (2017). source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“In both cases, it is important to recognize that the risk associated with a high polygenic score may not reflect a single underlying mechanism, but rather the combined influence of multiple pathways.28”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
What the sources say
- Not checked yetcites [28] Khera, A. V. & Kathiresan, S. Is coronary atherosclerosis one disease or many? Setting realistic expectations for precision medicine. Circulation 135, 1005–1007 (2017). source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“For example, we previously showed that a high polygenic risk for CAD may be offset by either of two interventions: adherence to a healthy lifestyle or cholesterol-lowering therapy with statin medications.19–21”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
What the sources say
- Not checked yetcites [19] Khera, A. V. et al. Genetic risk, adherence to a healthy lifestyle, and coronary disease. N. Engl. J. Med. 375, 2349–2358 (2016). source
- Not checked yetcites [20] Mega, J. L. et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet 385, 2264–2271 (2015). source
- Not checked yetcites [21] Natarajan, P. et al. Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting. Circulation 135, 2091–2101 (2017). source
plainconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“UK Biobank samples were not included in any of the five discovery GWAS studies.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Online Methods: > Polygenic score derivation
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“An important example is the presence of a familial hypercholesterolemia mutation in 0.4% of the population, which confers an up to 3-fold increased risk for coronary artery disease (CAD).6”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
What the sources say
- Not checked yetcites [6] Abul-Husn, N. S. et al. Genetic identification of familial hypercholesterolemia within a single U.S. health care system. Science 354, pii: aaf7000 (2016). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Another example is the p.E508K missense mutation in HNF1A, with carrier frequency of 0.1% of the general population and 0.7% of Latinos,8 which confers up to 5-fold increased risk for type 2 diabetes.9”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
What the sources say
- Not checked yetcites [8] Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285–291 (2016). source
- Not checked yetcites [9] Estrada, K. et al. Association of a low-frequency variant in HNF1A with type 2 diabetes in a Latino population. JAMA 311, 2305–2314 (2014). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper relies on this without support.
The vast majority of common disease occurs in individuals without rare monogenic mutations.
“Although ascertainment of monogenic mutations can be highly relevant for carriers and their families, the vast majority of disease occurs in those without such mutations.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, integrated models of PRS together with other lifestyle and clinical factors have enabled clinicians to more accurately quantify the risk of heart attack for patients;”
From Clinical use of current polygenic risk scores may exacerbate health disparities (2019) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This enthusiasm is driven by observations that a polygenic burden of LDL-increasing SNPs can confer monogenic-equivalent risk of cardiovascular disease, with polygenic scores improving clinical models for risk assessment and statin prescription that can reduce coronary heart disease and improve healthcare delivery efficiency5–7.”
From Clinical use of current polygenic risk scores may exacerbate health disparities (2019) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Using polygenic scores, it is now possible to combine information from millions of genomic variants to identify people whose overall polygenic risk of coronary artery disease is as high as that of patients with monogenic lipid disorders such as familial hypercholesterolemia [23].”
From Interpreting polygenic scores, polygenic adaptation, and human phenotypic differences (2019) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For example, they have contributed new approaches to risk prediction for adverse phenotypes related to heart disease [21–23].”
From Interpreting polygenic scores, polygenic adaptation, and human phenotypic differences (2019) · cites this paper as [23]
In the citing paper
“As described below, findings from GWAS have increasing translational impact through identification of novel therapeutic targets67, prioritization (and deprioritization) of existing ones68 and development of polygenic scores that quantify individual genetic risk69.”
From A brief history of human disease genetics (2020) · cites this paper as [69]
In the citing paper
“The development of robust polygenic scores for several common diseases has been catalysed by more precise per-variant effect estimates from larger GWAS datasets, improved algorithms for combining information across millions of single-nucleotide polymorphisms, and large-scale biobanks that support score validation69,146,147.”
From A brief history of human disease genetics (2020) · cites this paper as [69]
In the citing paper
“For example, a genome-wide polygenic score for heart attack, incorporating 6.6 million variants, indicates that 5% of European-descent individuals have a risk of future cardiac events equivalent to that seen in those with less frequent monogenic forms of hypercholesterolaemia69.”
From A brief history of human disease genetics (2020) · cites this paper as [69]
In the citing paper
“This paper used large-scale genetic data to demonstrate the clinical potential of the polygenic scores that can be constructed for many common diseases, emphasizing that, in some situations, the lifetime risk of disease for those with the highest scores approaches that of established monogenic disease.”
From A brief history of human disease genetics (2020) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Online Methods: > Statistical analysis within the testing dataset
“For each disease, the GPS with the best discriminative capacity in the testing dataset was calculated in the testing dataset of 288,278 participants”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Online Methods: > Testing cohort
“The testing dataset was comprised of 288,978 UK Biobank Phase 2 participants distinct from those in the validation dataset described above.”
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
A global reference for human genetic variation
The 1000 Genomes Project Consortium, authors, C., Auton, A., Abecasis, G. R., Steering committee, Altshuler, D. M., Durbin, R. M., Abecasis, G. R., Bentley, D. R., Chakravarti, A., et al. (2015) · Nature · doi:10.1038/nature15393 · Cited by 18,247
Self-citationVos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001779 · Cited by 12,728
Second-generation PLINK: rising to the challenge of larger and richer datasets
Chang, C. C., Chow, C. C., Tellier, L. C., Vattikuti, S., Purcell, S. M., & Lee, J. J. (2015) · Gigascience · doi:10.1186/s13742-015-0047-8 · Cited by 12,709
Analysis of protein-coding genetic variation in 60,706 humans
Exome Aggregation Consortium, Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., O’Donnell-Luria, A. H., Ware, J. S., Hill, A. J., et al. (2016) · Nature · doi:10.1038/nature19057 · Cited by 9,587
Self-citationVos, T., Allen, C., Arora, M., Barber, R. M., Bhutta, Z. A., Brown, A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31678-6 · Cited by 7,253
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H. G., Cigarroa, J. E., Cleveland, J. C., CONTI, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000041 · Cited by 7,145
Self-citationCommon polygenic variation contributes to risk of schizophrenia and bipolar disorder
The International Schizophrenia Consortium (2009) · Nature · doi:10.1038/nature08185 · Cited by 4,821
Genetic studies of body mass index yield new insights for obesity biology
Study, T. L. C., Locke, A. E., The ADIPOGen Consortium, The AGEN-BMI Working Group, The CARDIOGRAMplusC4D Consortium, The CKDGen Consortium, The, G. L. G. C., The, I. C. B. P., The MAGIC Investigators, The MuTHER Consortium, et al. (2015) · Nature · doi:10.1038/nature14177 · Cited by 4,534
Self-citation
Cited by
Sorted by citations
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485
Gelder, I. C. V., Rienstra, M., Bunting, K. V., Casado-Arroyo, R., Caso, V., Crijns, H. J. G. M., Potter, T. J. R. D., Dwight, J., Guasti, L., Hanke, T., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae176 · Cited by 3,594
Applications of machine learning in drug discovery and development
Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., Li, B., Madabhushi, A., Shah, P., Spitzer, M., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0024-5 · Cited by 3,228
Clinical use of current polygenic risk scores may exacerbate health disparities
Martin, A. R., Kanai, M., Kamatani, Y., Okada, Y., Neale, B. M., & Daly, M. J. (2019) · Nature Genetics · doi:10.1038/s41588-019-0379-x · Cited by 2,821
Zondervan, K. T., Becker, C. M., & Missmer, S. A. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1810764 · Cited by 2,249
Benefits and limitations of genome-wide association studies
Tam, V., Patel, N. K., Turcotte, M., Bossé, Y., Paré, G., & Meyre, D. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0127-1 · Cited by 2,208
Polygenic prediction via Bayesian regression and continuous shrinkage priors
Ge, T., Chen, C.-Y., Ni, Y., Feng, Y.-C. A., & Smoller, J. W. (2019) · Nature Communications · doi:10.1038/s41467-019-09718-5 · Cited by 1,922
Tutorial: a guide to performing polygenic risk score analyses
Choi, S. W., Mak, T. S. H., & O’Reilly, P. F. (2020) · Nature Protocols · doi:10.1038/s41596-020-0353-1 · Cited by 2,058
Self-citationGenome-wide association studies
Uffelmann, E., Huang, Q. Q., Munung, N. S., de Vries, J., Okada, Y., Martin, A. R., Martin, H. C., Lappalainen, T., & Posthuma, D. (2021) · Nature Reviews Methods Primers · doi:10.1038/s43586-021-00056-9 · Cited by 1,849
The personal and clinical utility of polygenic risk scores
Torkamani, A., Wineinger, N. E., & Topol, E. J. (2018) · Nature Reviews Genetics · doi:10.1038/s41576-018-0018-x · Cited by 1,655
The Missing Diversity in Human Genetic Studies
Sirugo, G., Williams, S. M., & Tishkoff, S. A. (2019) · Cell · doi:10.1016/j.cell.2019.02.048 · Cited by 1,516
Polygenic risk scores: from research tools to clinical instruments
Lewis, C. M., & Vassos, E. (2020) · Genome Medicine · doi:10.1186/s13073-020-00742-5 · Cited by 1,360
The genetic architecture of Parkinson's disease
Blauwendraat, C., Nalls, M. A., & Singleton, A. B. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30287-x · Cited by 1,114
Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes
Mavaddat, N., Michailidou, K., Dennis, J., Lush, M. J., Fachal, L., Lee, A., Tyrer, J. P., Chen, T., Wang, Q., Bolla, M. K., et al. (2018) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2018.11.002 · Cited by 1,083
Genetic analyses of diverse populations improves discovery for complex traits
Wojcik, G. L., Graff, M., Nishimura, K. K., Tao, R., Haessler, J., Gignoux, C. R., Highland, H. M., Patel, Y. M., Sorokin, E. P., Avery, C. L., et al. (2019) · Nature · doi:10.1038/s41586-019-1310-4 · Cited by 1,033
DNA methylation aging clocks: challenges and recommendations
Bell, C. G., Lowe, R., Adams, P. D., Baccarelli, A. A., Beck, S., Bell, J. T., Christensen, B. C., Gladyshev, V. N., Heijmans, B. T., Horvath, S., et al. (2019) · Genome Biology · doi:10.1186/s13059-019-1824-y · Cited by 1,025
The power of genetic diversity in genome-wide association studies of lipids
Graham, S. E., Clarke, S. L., Wu, K.-H. H., Kanoni, S., Zajac, G. J. M., Ramdas, S., Surakka, I., Ntalla, I., Vedantam, S., Winkler, T. W., et al. (2021) · Nature · doi:10.1038/s41586-021-04064-3 · Cited by 972
Andrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0105-0 · Cited by 924
Machine Learning in Drug Discovery: A Review
Dara, S., Dhamercherla, S., Jadav, S. S., Babu, C. M., & Ahsan, M. J. (2021) · Artificial Intelligence Review · doi:10.1007/s10462-021-10058-4 · Cited by 893
Early Detection of Pancreatic Cancer: Opportunities and Challenges
Singhi, A. D., Koay, E. J., Chari, S. T., & Maitra, A. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.259 · Cited by 841
Genomic Risk Prediction of Coronary Artery Disease in 480,000 Adults
Inouye, M., Abraham, G., Nelson, C. P., Wood, A., Sweeting, M. J., Dudbridge, F., Lai, F. Y., Kaptoge, S. K., Brożyńska, M., Wang, T., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.07.079 · Cited by 830
Peterson, R. E., Kuchenbaecker, K., Walters, R. K., Chen, C.-Y., Popejoy, A. B., Periyasamy, S., Lam, M., Iyegbe, C., Strawbridge, R. J., Brick, L., et al. (2019) · Cell · doi:10.1016/j.cell.2019.08.051 · Cited by 797
Polygenic Prediction of Weight and Obesity Trajectories from Birth to Adulthood
Khera, A. V., Chaffin, M., Wade, K. H., Zahid, S., Brancale, J., Xia, R., Distefano, M., Senol-Cosar, O., Haas, M. E., Bick, A., et al. (2019) · Cell · doi:10.1016/j.cell.2019.03.028 · Cited by 789
Self-citationThe Lancet Commission on diabetes: using data to transform diabetes care and patient lives
Chan, J. C. N., Lim, L.-L., Wareham, N. J., Shaw, J. E., Orchard, T. J., Zhang, P., Lau, E. S. H., Eliasson, B., Kong, A. P. S., Ezzati, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32374-6 · Cited by 793
Genetics of 35 blood and urine biomarkers in the UK Biobank
Sinnott-Armstrong, N., Tanigawa, Y., Amar, D., Mars, N., Benner, C., Aguirre, M., Venkataraman, G. R., Wainberg, M., Ollila, H. M., Kiiskinen, T., et al. (2021) · Nature Genetics · doi:10.1038/s41588-020-00757-z · Cited by 744
LDpred2: better, faster, stronger
Privé, F., Arbel, J., & Vilhjálmsson, B. J. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btaa1029 · Cited by 726
Aragam, K. G., Jiang, T., Goel, A., Kanoni, S., Wolford, B. N., Atri, D. S., Weeks, E. M., Wang, M., Hindy, G., Zhou, W., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01233-6 · Cited by 738
Self-citationImproving polygenic prediction in ancestrally diverse populations
Ruan, Y., Lin, Y.-F., Feng, Y.-C. A., Chen, C.-Y., Lam, M., Guo, Z., Initiatives, S. G. A., Ahn, Y. M., Akiyama, K., Arai, M., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01054-7 · Cited by 707
A brief history of human disease genetics
Claussnitzer, M., Cho, J. H., Collins, R., Cox, N. J., Dermitzakis, E. T., Hurles, M. E., Kathiresan, S., Kenny, E. E., Lindgren, C. M., MacArthur, D. G., et al. (2020) · Nature · doi:10.1038/s41586-019-1879-7 · Cited by 697
Self-citationThe Polygenic Score Catalog as an open database for reproducibility and systematic evaluation
Lambert, S. A., Gil, L., Jupp, S., Ritchie, S. C., Xu, Y., Buniello, A., McMahon, A., Abraham, G., Chapman, M., Parkinson, H., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00783-5 · Cited by 709
Stroke genetics informs drug discovery and risk prediction across ancestries
Mishra, A., Malik, R., Hachiya, T., Jürgenson, T., Namba, S., Posner, D. C., Kamanu, F., Koido, M., Grand, Q. L., Shi, M., et al. (2022) · Nature · doi:10.1038/s41586-022-05165-3 · Cited by 623
Cano-Gamez, E., & Trynka, G. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00424 · Cited by 613
Patel, A. P., Wang, M., Pirruccello, J. P., Ellinor, P. T., Ng, K., Kathiresan, S., & Khera, A. V. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.120.315291 · Cited by 567
Self-citationTowards clinical utility of polygenic risk scores
Lambert, S. A., Abraham, G., & Inouye, M. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz187 · Cited by 586
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Bénétos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab154 · Cited by 586
15 years of GWAS discovery: Realizing the promise
Abdellaoui, A., Yengo, L., Verweij, K. J. H., & Visscher, P. M. (2023) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2022.12.011 · Cited by 570
Atlas of plasma NMR biomarkers for health and disease in 118,461 individuals from the UK Biobank
Julkunen, H., Cichońska, A., Tiainen, M., Koskela, H. T., Nybo, K., Mäkelä, V., Nokso-Koivisto, J., Kristiansson, K., Perola, M., Salomaa, V. V., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36231-7 · Cited by 550
Ishigaki, K., Akiyama, M., Kanai, M., Takahashi, A., Kawakami, E., Sugishita, H., Sakaue, S., Matoba, N., Low, S.-K., Okada, Y., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0640-3 · Cited by 508
Trans effects on gene expression can drive omnigenic inheritance
Liu, X., Li, Y. I., & Pritchard, J. K. (2019) · Cell · doi:10.1016/j.cell.2019.04.014 · Cited by 523
Artificial Intelligence and Personalized Medicine
Schork, N. J. (2019) · Cancer treatment and research · doi:10.1007/978-3-030-16391-4_11 · Cited by 531
A Modern Approach to Dyslipidemia
Berberich, A. J., & Hegele, R. A. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab037 · Cited by 529
FinnGen, Mars, N., Koskela, J. T., Ripatti, P., Kiiskinen, T., Havulinna, A. S., Lindbohm, J. V., Ahola‐Olli, A., Kurki, M., Karjalainen, J. M., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0800-0 · Cited by 498
Genetics meets proteomics: perspectives for large population-based studies
Suhre, K., McCarthy, M. I., & Schwenk, J. M. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-020-0268-2 · Cited by 478
Elliott, J., Bodinier, B., Bond, T. A., Chadeau‐Hyam, M., Εvangelou, Ε., Moons, K. G. M., Dehghan, A., Muller, D. C., Elliott, P., & Tzoulaki, I. (2020) · JAMA · doi:10.1001/jama.2019.22241 · Cited by 472
Association of Premature Natural and Surgical Menopause With Incident Cardiovascular Disease
Honigberg, M. C., Zekavat, S. M., Aragam, K. G., Finneran, P., Klarin, D. M., Bhatt, D. L., Januzzi, J. L., Scott, N. S., & Natarajan, P. (2019) · JAMA · doi:10.1001/jama.2019.19191 · Cited by 480
Self-citationImproving reporting standards for polygenic scores in risk prediction studies
Wand, H., Lambert, S. A., Tamburro, C. P., Iacocca, M. A., O’Sullivan, J. W., Sillari, C. H., Kullo, I. J., Rowley, R. K., Dron, J. S., Brockman, D., et al. (2021) · Nature · doi:10.1038/s41586-021-03243-6 · Cited by 484
Self-citationVariable prediction accuracy of polygenic scores within an ancestry group
Mostafavi, H., Harpak, A., Agarwal, I., Conley, D., Pritchard, J. K., & Przeworski, M. (2020) · eLife · doi:10.7554/elife.48376 · Cited by 457
Defining the genetic, genomic, cellular, and diagnostic architectures of psychiatric disorders
Sullivan, P. F., & Geschwind, D. H. (2019) · Cell · doi:10.1016/j.cell.2019.01.015 · Cited by 452
“, for prostate cancer, breast cancer, cardiovascular disease, and type 2 diabetes mellitus) (Grönberg et al., 2015; Khera et al., 2018; McCarthy and Mahajan, 2018; Shieh et al., 2016).”
BackgroundPolygenic background modifies penetrance of monogenic variants for tier 1 genomic conditions
Fahed, A. C., Wang, M., Homburger, J. R., Patel, A. P., Bick, A. G., Neben, C. L., Lai, C., Brockman, D., Philippakis, A., Ellinor, P. T., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17374-3 · Cited by 459
Self-citationThompson, D. J., Wells, D., Selzam, S., Peneva, I., Moore, R., Sharp, K., Tarran, W. A., Beard, E. J., Riveros-Mckay, F., Giner-Delgado, C., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0307270 · Cited by 437
O’Sullivan, J. W., Raghavan, S., Márquez‐Luna, C., Luzum, J. A., Damrauer, S. M., Ashley, E. A., O’Donnell, C. J., Willer, C. J., & Natarajan, P. (2022) · Circulation · doi:10.1161/cir.0000000000001077 · Cited by 443
Self-citationResponsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps
Polygenic Risk Score Task Force of the International Common Disease Alliance, Adeyemo, A., Balaconis, M. K., Darnes, D. R., Fatumo, S., Granados Moreno, P., Hodonsky, C. J., Inouye, M., Kanai, M., Kato, K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01549-6 · Cited by 413
Wilde, A. A. M., Semsarian, C., Márquez, M. F., Shamloo, A. S., Ackerman, M. J., Ashley, E. A., Sternick, E. B., Barajas-Martínez, H., Behr, E. R., Bezzina, C. R., et al. (2022) · EP Europace · doi:10.1093/europace/euac030 · Cited by 421
Self-citationUnderspecification Presents Challenges for Credibility in Modern Machine Learning
D'Amour, A., Heller, K., Moldovan, D., Adlam, B., Alipanahi, B., Beutel, A., Chen, C., Deaton, J., Eisenstein, J., Hoffman, M. D., et al. (2020) · arXiv · doi:10.48550/arxiv.2011.03395 · Cited by 398
Update on NAFLD genetics: From new variants to the clinic
Trépo, E., & Valenti, L. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.02.020 · Cited by 393
Genetic correlations of polygenic disease traits: from theory to practice
van Rheenen, W., Peyrot, W. J., Schork, A. J., Lee, S., & Wray, N. R. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0137-z · Cited by 402
Epidemiology and modifiable risk factors for atrial fibrillation
Elliott, A. D., Middeldorp, M. E., Gelder, I. C. V., Albert, C. M., & Sanders, P. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00820-8 · Cited by 392
Musunuru, K., Hershberger, R. E., Day, S. M., Klinedinst, N. J., Landstrom, A. P., Parikh, V. N., Prakash, S. K., Semsarian, C., & Sturm, A. C. (2020) · Circulation Genomic and Precision Medicine · doi:10.1161/hcg.0000000000000067 · Cited by 382
From Basic Science to Clinical Application of Polygenic Risk Scores: A Primer
Wray, N. R., Lin, T., Austin, J., McGrath, J. J., Hickie, I. B., Murray, G. K., & Visscher, P. M. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3049 · Cited by 367
Sharp, S. A., Rich, S. S., Wood, A. R., Jones, S. E., Beaumont, R. N., Harrison, J. W., Schneider, D. A., Locke, J. M., Tyrrell, J., Weedon, M. N., et al. (2019) · Diabetes Care · doi:10.2337/dc18-1785 · Cited by 366
Precision medicine in 2030—seven ways to transform healthcare
Denny, J. C., & Collins, F. S. (2021) · Cell · doi:10.1016/j.cell.2021.01.015 · Cited by 362
Sohail, M., Maier, R. M., Ganna, A., Bloemendal, A., Martin, A. R., Turchin, M. C., Chiang, C. W., Hirschhorn, J., Daly, M. J., Patterson, N., et al. (2019) · eLife · doi:10.7554/elife.39702 · Cited by 359
Personalized Medicine and the Power of Electronic Health Records
Abul-Husn, N. S., & Kenny, E. E. (2019) · Cell · doi:10.1016/j.cell.2019.02.039 · Cited by 355
Tcheandjieu, C., Zhu, X., Hilliard, A. T., Clarke, S. L., Napolioni, V., Ma, S., Lee, K. M., Fang, H., Chen, F., Lu, Y., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01891-3 · Cited by 363
Self-citationKoyama, S., Ito, K., Terao, C., Akiyama, M., Horikoshi, M., Momozawa, Y., Matsunaga, H., Ieki, H., Ozaki, K., Onouchi, Y., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0705-3 · Cited by 353
Armoundas, A. A., Narayan, S. M., Arnett, D. K., Spector-Bagdady, K., Bennett, D. A., Celi, L. A., Friedman, P. A., Gollob, M. H., Hall, J. L., Kwitek, A. E., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001201 · Cited by 347
Craig, J. E., Han, X., Qassim, A., Hassall, M., Bailey, J. N. C., Kinzy, T. G., Khawaja, A. P., An, J., Marshall, H. N., Gharahkhani, P., et al. (2020) · Nature Genetics · doi:10.1038/s41588-019-0556-y · Cited by 346
Principles and methods for transferring polygenic risk scores across global populations
Kachuri, L., Chatterjee, N., Hirbo, J. B., Schaid, D. J., Martin, I. K., Kullo, I. J., Kenny, E. E., Paşaniuc, B., Auer, P. L., Conomos, M. P., et al. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-023-00637-2 · Cited by 366
Strategic vision for improving human health at The Forefront of Genomics
Green, E. D., Gunter, C., Biesecker, L. G., Francesco, V. D., Easter, C. L., Feingold, E. A., Felsenfeld, A. L., Kaufman, D., Ostrander, E. A., Pavan, W. J., et al. (2020) · Nature · doi:10.1038/s41586-020-2817-4 · Cited by 352
Mosley, J. D., Gupta, D. K., Tan, J., Yao, J., Wells, Q. S., Shaffer, C. M., Kundu, S., Robinson‐Cohen, C., Psaty, B. M., Rich, S. S., et al. (2020) · JAMA · doi:10.1001/jama.2019.21782 · Cited by 338
Multilevel omics for the discovery of biomarkers and therapeutic targets for stroke
Montaner, J., Ramiro, L., Simats, A., Tiedt, S., Makris, K., Jickling, G. C., Debette, S., Sanchez, J., & Bustamante, A. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0350-6 · Cited by 338
Marijon, É., Narayanan, K., Smith, K. L., Barra, S., Basso, C., Blom, M. T., Crotti, L., d’Ávila, A., Deo, R., Dumas, F., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00875-9 · Cited by 346
Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores
de Rojas, I., Moreno-Grau, S., Tesi, N., Grenier-Boley, B., Andrade, V., Jansen, I. E., Pedersen, N. L., Stringa, N., Zettergren, A., Hernández, I., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22491-8 · Cited by 324
A decade of genome-wide association studies for coronary artery disease: the challenges ahead
Erdmann, J., Kessler, T., Venegas, L. M., & Schunkert, H. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy084 · Cited by 331
The Missing Diversity in Human Genetic Studies
Sirugo, G., Williams, S. M., & Tishkoff, S. A. (2019) · Cell · doi:10.1016/j.cell.2019.04.032 · Cited by 317
Okamura, T., Tsukamoto, K., Arai, H., Fujioka, Y., Ishigaki, Y., Koba, S., Ohmura, H., Shoji, T., Yokote, K., Yoshida, H., et al. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2022 · Cited by 345
Khera, A. V., Chaffin, M., Zekavat, S. M., Collins, R. L., Roselli, C., Natarajan, P., Lichtman, J. H., D’Onofrio, G., Mattera, J., Dreyer, R., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.035658 · Cited by 315
Self-citationExome sequencing of 20,791 cases of type 2 diabetes and 24,440 controls
Platform, B. G., Flannick, J., DiscovEHR Collaboration, CHARGE, LuCamp, ProDiGY, GoT2D, ESP, SIGMA-T2D, T2D-GENES, et al. (2019) · Nature · doi:10.1038/s41586-019-1231-2 · Cited by 304
A multi-ancestry polygenic risk score improves risk prediction for coronary artery disease
Patel, A. P., Wang, M., Ruan, Y., Koyama, S., Clarke, S. L., Yang, X., Tcheandjieu, C., Agrawal, S., Fahed, A. C., Ellinor, P. T., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02429-x · Cited by 309
Self-citationGenetic Risk Scores for Diabetes Diagnosis and Precision Medicine
Udler, M. S., McCarthy, M. I., Florez, J. C., & Mahajan, A. (2019) · Endocrine Reviews · doi:10.1210/er.2019-00088 · Cited by 302
Deconstructing a Syndrome: Genomic Insights Into PCOS Causal Mechanisms and Classification
Dapas, M., & Dunaif, A. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac001 · Cited by 300
Genomics of disease risk in globally diverse populations
Gurdasani, D., Barroso, I., Zeggini, E., & Sandhu, M. S. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0144-0 · Cited by 312
Incomplete Penetrance and Variable Expressivity: From Clinical Studies to Population Cohorts
Kingdom, R., & Wright, C. F. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.920390 · Cited by 326
The influence of evolutionary history on human health and disease
Benton, M. L., Abraham, A., LaBella, A. L., Abbot, P., Rokas, A., & Capra, J. A. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-020-00305-9 · Cited by 291
Deconstructing the sources of genotype-phenotype associations in humans
Young, A. I., Benonisdottir, S., Przeworski, M., & Kong, A. (2019) · Science · doi:10.1126/science.aax3710 · Cited by 288
Population genetics of the coral Acropora millepora : Toward genomic prediction of bleaching
Fuller, Z. L., Mocellin, V. J. L., Morris, L. A., Cantin, N. E., Shepherd, J., Sarre, L. A., Peng, J., Liao, Y., Pickrell, J. K., Andolfatto, P., et al. (2020) · Science · doi:10.1126/science.aba4674 · Cited by 293
Tadros, R., Francis, C., Xu, X. Y., Vermeer, A. M. C., Harper, A. R., Huurman, R., Bisabu, K. K., Walsh, R., Hoorntje, E. T., Rijdt, W. P. T., et al. (2021) · Nature Genetics · doi:10.1038/s41588-020-00762-2 · Cited by 288
Wilde, A. A. M., Semsarian, C., Márquez, M. F., Shamloo, A. S., Ackerman, M. J., Ashley, E. A., Sternick, E. B., Barajas-Martínez, H., Behr, E. R., Bezzina, C. R., et al. (2022) · Heart Rhythm · doi:10.1016/j.hrthm.2022.03.1225 · Cited by 287
Self-citationThompson, D. J., Wells, D., Selzam, S., Peneva, I., Moore, R., Sharp, K., Tarran, W. A., Beard, E. J., Riveros-Mckay, F., Giner-Delgado, C., et al. (2022) · doi:10.1101/2022.06.16.22276246 · Cited by 280
Timmers, P. R., Mounier, N., Lall, K., Fischer, K., Ning, Z., Feng, X., Bretherick, A. D., Clark, D. W., eQTLGen Consortium, Agbessi, M., et al. (2019) · eLife · doi:10.7554/elife.39856 · Cited by 259
Advancing the use of genome-wide association studies for drug repurposing
Reay, W. R., & Cairns, M. J. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00387-z · Cited by 284
Risk prediction of late-onset Alzheimer’s disease implies an oligogenic architecture
Zhang, Q., Sidorenko, J., Couvy-Duchesne, B., Marioni, R. E., Wright, M. J., Goate, A. M., Marcora, E., Huang, K.-L., Porter, T., Laws, S. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18534-1 · Cited by 272
Agrawal, M., Spencer, E. A., Colombel, J., & Ungaro, R. C. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.04.063 · Cited by 272
Dissecting diagnostic heterogeneity in depression by integrating neuroimaging and genetics
Buch, A. M., & Liston, C. M. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-00789-3 · Cited by 289
Genetics of mitochondrial diseases: Identifying mutations to help diagnosis
Stenton, S. L., & Prokisch, H. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102784 · Cited by 291
Miguel-Escalada, I., Bonàs‐Guarch, S., Cebola, I., Ponsa-Cobas, J., Mendieta-Esteban, J., Atla, G., Javierre, B. M., Rolando, D., Farabella, I., Morgan, C. C., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0457-0 · Cited by 269
Jin, G., Lv, J., Yang, M., Wang, M., Zhu, M., Wang, T., Yan, C., Yu, C., Ding, Y., Li, G., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30460-5 · Cited by 259
Andreassen, O. A., Hindley, G., Frei, O., & Smeland, O. B. (2023) · World Psychiatry · doi:10.1002/wps.21034 · Cited by 284
Genomic Medicine–Progress, Pitfalls, and Promise
Shendure, J., Findlay, G. M., & Snyder, M. W. (2019) · Cell · doi:10.1016/j.cell.2019.02.003 · Cited by 263
Metadata
- Authors
- Khera, A. V., Chaffin, M., Aragam, K. G., Haas, M. E., Roselli, C., Choi, S. H., Natarajan, P., Lander, E. S., Lubitz, S. A., Ellinor, P. T., & Kathiresan, S.
- Affiliations
- Broad Institute (US)
- Corresponding author
- Kathiresan, Sekar
- ORCID
- Venue
- Nature Genetics
- Published
- 2018-08-13
- Volume
- 50
- Issue
- 9
- Pages
- 1219-1224
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- PMC
- PMC6128408
- OpenAlex
- W2886752110
- Semantic Scholar
- d5eb49c11d070114e2ff46224099895c6b4b1558
- Cited by
- 2,953
- References
- 46
- Citations by year
- 2026: 276 · 2025: 290 · 2024: 363 · 2023: 362 · 2022: 433 · 2021: 411 · 2020: 451 · 2019: 307 · 2018: 57
- FWCI
- 189.86
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, other-oa)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- PMC
- Funders
- Doris Duke Charitable Foundation (2014105)
- Massachusetts General Hospital (HL007208)
- Harvard Catalyst (TR001100)
- Vertex Pharmaceuticals
- KR Foundation
- National Institutes of Health (KL2TR001100, HL0-07734, HL007208, T32-HL007734)
- National Heart, Lung, and Blood Institute (R01HL127564, HL007208, HL127564, R01HL128914, T-32HL007734, K08HL140203, HL007734, K23HL114724, K24HL105780, R01HL142711, R01HL092577, T32HL007208, R01HL139731)
- National Human Genome Research Institute (UM1HG008895)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and phenotypic traits in livestock
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Keywords
- polygenic risk score, monogenic mutations, common diseases, coronary artery disease, atrial fibrillation, type 2 diabetes, inflammatory bowel disease, breast cancer, high-risk individuals, clinical risk stratification
- MeSH terms
- Adult, Aged, Disease, Female, Humans, Male, Middle Aged, Mutation, Risk Factors, Genetic Predisposition to Disease, Multifactorial Inheritance, Polymorphism, Single Nucleotide, Genome-Wide Association Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
